Elusys picks up $50.2M BARDA funds to advance anthrax antitoxin
This article was originally published in Scrip
Executive Summary
Elusys Therapeutics scored another $50.2 million under a broader contract with the US government to advance the development of the privately held firm's experimental inhalational anthrax antitoxin Anthim (ETI-204), a high-affinity deimmunized monoclonal antibody.